Literature DB >> 26541523

Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease.

David Montani1, Edmund M Lau2, Alexis Descatha3, Xavier Jaïs4, Laurent Savale4, Pascal Andujar5, Lynda Bensefa-Colas6, Barbara Girerd4, Inès Zendah7, Jerome Le Pavec8, Andrei Seferian4, Frédéric Perros4, Peter Dorfmüller9, Elie Fadel10, Florent Soubrier11, Oliver Sitbon4, Gérald Simonneau4, Marc Humbert4.   

Abstract

Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary hypertension characterised by predominant remodelling of pulmonary venules. Bi-allelic mutations in the eukaryotic translation initiation factor 2α kinase 4 (EIF2AK4) gene were recently described as the major cause of heritable PVOD, but risk factors associated with PVOD remain poorly understood. Occupational exposures have been proposed as a potential risk factor for PVOD, but epidemiological studies are lacking.A case-control study was conducted in consecutive PVOD (cases, n=33) and pulmonary arterial hypertension patients (controls, n=65). Occupational exposure was evaluated via questionnaire interview with blinded assessments using an expert consensus approach and a job exposure matrix (JEM).Using the expert consensus approach, PVOD was significantly associated with occupational exposure to organic solvents (adjusted OR 12.8, 95% CI 2.7-60.8), with trichloroethylene being the main agent implicated (adjusted OR 8.2, 95% CI 1.4-49.4). JEM analysis independently confirmed the association between PVOD and trichloroethylene exposure. Absence of significant trichloroethylene exposure was associated with a younger age of disease (54.8±21.4 years, p=0.037) and a high prevalence of harbouring bi-allelic EIF2AK4 mutations (41.7% versus 0%, p=0.015).Occupational exposure to organic solvents may represent a novel risk factor for PVOD. Genetic background and environmental exposure appear to influence the phenotypic expression of the disease.
Copyright ©ERS 2015.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26541523     DOI: 10.1183/13993003.00814-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  12 in total

1.  Rapidly progressive fatal hypoxia in a young woman.

Authors:  Aaron J Sohn; Joseph M Guileyardo; Alastair J Moore; Kenneth A Ausloos; Chetan A Naik
Journal:  Proc (Bayl Univ Med Cent)       Date:  2021-01-22

Review 2.  'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension.

Authors:  Emilia M Swietlik; Matina Prapa; Jennifer M Martin; Divya Pandya; Kathryn Auckland; Nicholas W Morrell; Stefan Gräf
Journal:  Genes (Basel)       Date:  2020-11-26       Impact factor: 4.096

Review 3.  Molecular basis of the association between transcription regulators nuclear respiratory factor 1 and inhibitor of DNA binding protein 3 and the development of microvascular lesions.

Authors:  Christian Michael Perez; Quentin Felty
Journal:  Microvasc Res       Date:  2022-02-07       Impact factor: 3.514

4.  Polychlorinated Biphenyls and Pulmonary Hypertension.

Authors:  Hamza Assaggaf; Changwon Yoo; Roberto G Lucchini; Steven M Black; Munerah Hamed; Faisal Minshawi; Quentin Felty
Journal:  Int J Environ Res Public Health       Date:  2022-04-13       Impact factor: 4.614

Review 5.  Gender, Estrogen, and Obliterative Lesions in the Lung.

Authors:  Hamza Assaggaf; Quentin Felty
Journal:  Int J Endocrinol       Date:  2017-04-02       Impact factor: 3.257

6.  Haemodynamic definitions and updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; David Montani; David S Celermajer; Christopher P Denton; Michael A Gatzoulis; Michael Krowka; Paul G Williams; Rogerio Souza
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

Review 7.  DNA Damage and Pulmonary Hypertension.

Authors:  Benoît Ranchoux; Jolyane Meloche; Roxane Paulin; Olivier Boucherat; Steeve Provencher; Sébastien Bonnet
Journal:  Int J Mol Sci       Date:  2016-06-22       Impact factor: 5.923

Review 8.  EIF2AK4 mutation in pulmonary veno-occlusive disease: A case report and review of the literature.

Authors:  Li Liang; Guofeng Ma; Kai Chen; Yangxiang Liu; Xiaohong Wu; Kejing Ying; Ruifeng Zhang
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

9.  Good response to PAH-targeted drugs in a PVOD patient carrying Biallelic EIF2AK4 mutation.

Authors:  Li Liang; Hua Su; Xiuqing Ma; Ruifeng Zhang
Journal:  Respir Res       Date:  2018-10-01

10.  Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension.

Authors:  Charaka Hadinnapola; Marta Bleda; Matthias Haimel; Nicholas Screaton; Andrew Swift; Peter Dorfmüller; Stephen D Preston; Mark Southwood; Jules Hernandez-Sanchez; Jennifer Martin; Carmen Treacy; Katherine Yates; Harm Bogaard; Colin Church; Gerry Coghlan; Robin Condliffe; Paul A Corris; Simon Gibbs; Barbara Girerd; Simon Holden; Marc Humbert; David G Kiely; Allan Lawrie; Rajiv Machado; Robert MacKenzie Ross; Shahin Moledina; David Montani; Michael Newnham; Andrew Peacock; Joanna Pepke-Zaba; Paula Rayner-Matthews; Olga Shamardina; Florent Soubrier; Laura Southgate; Jay Suntharalingam; Mark Toshner; Richard Trembath; Anton Vonk Noordegraaf; Martin R Wilkins; Stephen J Wort; John Wharton; Stefan Gräf; Nicholas W Morrell
Journal:  Circulation       Date:  2017-09-28       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.